Cargando…

Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths worldwide and its incidence is rising. Percutaneous locoregional therapies, such as radiofrequency ablation and microwave ablation, are widely used as curative treatment options for patients with small HCC, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dumolard, Lucile, Ghelfi, Julien, Roth, Gael, Decaens, Thomas, Macek Jilkova, Zuzana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352237/ https://www.ncbi.nlm.nih.gov/pubmed/32575734 http://dx.doi.org/10.3390/ijms21124398

Ejemplares similares

Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment
por: Mroweh, Mariam, et al.
Publicado: (2021)

Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

Modulating the Crosstalk between the Tumor and Its Microenvironment Using RNA Interference: A Treatment Strategy for Hepatocellular Carcinoma
por: Mroweh, Mariam, et al.
Publicado: (2020)

Reply to Comment on “Jilkova, Z.M.; et al. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges” Cancers 2019, 11, 1554
por: Macek Jilkova, Zuzana, et al.
Publicado: (2020)

Chronic Intermittent Hypoxia Increases Cell Proliferation in Hepatocellular Carcinoma
por: Carreres, Lydie, et al.
Publicado: (2022)

Immune checkpoints on T and NK cells in the context of HBV infection: Landscape, pathophysiology and therapeutic exploitation
por: Dumolard, Lucile, et al.
Publicado: (2023)

Idarubicin vs doxorubicin in transarterial chemoembolization of intermediate stage hepatocellular carcinoma
por: Roth, Gaël Stéphane, et al.
Publicado: (2020)

Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model
por: Kurma, Keerthi, et al.
Publicado: (2022)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma
por: Jilkova, Zuzana Macek, et al.
Publicado: (2018)

Gamma delta T cells in hepatocellular carcinoma: Sunrise of new therapy based on Vδ2 T cells?
por: Macek Jilkova, Zuzana
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma
por: Roth, Gael S., et al.
Publicado: (2022)

Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019)

DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma
por: Kurma, Keerthi, et al.
Publicado: (2021)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
por: Roth, Gaël S., et al.
Publicado: (2021)

Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C
por: Malov, S.I., et al.
Publicado: (2021)

Sex Differences in Spontaneous Degranulation Activity of Intrahepatic Natural Killer Cells during Chronic Hepatitis B: Association with Estradiol Levels
por: Macek Jilkova, Zuzana, et al.
Publicado: (2017)

Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization
por: Roth, Gael, et al.
Publicado: (2022)

Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery
por: Shiina, Shuichiro, et al.
Publicado: (2018)

Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria
por: Zhou, Yanzhao, et al.
Publicado: (2021)

Circulating IL-13 Is Associated with De Novo Development of HCC in HCV-Infected Patients Responding to Direct-Acting Antivirals
por: Macek Jílková, Zuzana, et al.
Publicado: (2020)

GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
por: Brun, Sonia, et al.
Publicado: (2021)

GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer
por: Brun, Sonia, et al.
Publicado: (2021)

Immunomodulation by probiotics and prebiotics in hepatocellular carcinoma
por: Russo, Edda, et al.
Publicado: (2022)

Therapeutic Efficacy of Percutaneous Radiofrequency Ablation versus Microwave Ablation for Hepatocellular Carcinoma
por: Zhang, Lei, et al.
Publicado: (2013)

Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma
por: Kwak, Min Hwan, et al.
Publicado: (2022)

Percutaneous Thermal Ablation Therapy of Hepatocellular Carcinoma (HCC): Microwave Ablation (MWA) versus Laser-Induced Thermotherapy (LITT)
por: Adwan, Hamzah, et al.
Publicado: (2022)

Results of surgical and percutaneous ablative therapy for hepatocellular carcinoma in elderly patients
por: Selvaggi, F, et al.
Publicado: (2010)

Efficacy of percutaneous radiofrequency ablation (RFA) for hepatocellular carcinoma in elderly patients
por: Benevento, R, et al.
Publicado: (2011)

Percutaneous Radiofrequency Ablation with Multiple Electrodes for Medium-Sized Hepatocellular Carcinomas
por: Lee, Jung, et al.
Publicado: (2012)

Repeat hepatic resection versus percutaneous ablation for the treatment of recurrent hepatocellular carcinoma: meta-analysis
por: Yuan, Bao-Hong, et al.
Publicado: (2022)

Clinical Results, Risk Factors, and Future Directions of Ultrasound-Guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma
por: Dong, Tian-Tian, et al.
Publicado: (2023)

Predicting Outcome after Percutaneous Ablation for Early-Stage Hepatocellular Carcinoma Using Various Imaging Modalities
por: Shimizu, Ryo, et al.
Publicado: (2023)

Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease
por: Macek Jilkova, Zuzana, et al.
Publicado: (2021)

Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation
por: Jayant, Kumar, et al.
Publicado: (2020)

Percutaneous radiofrequency ablation is superior to hepatic resection in patients with small hepatocellular carcinoma
por: Zhang, Yan-Hua, et al.
Publicado: (2020)

Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma
por: Nishikawa, Hiroki, et al.
Publicado: (2011)

Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma
por: Bouza, Carmen, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_d5geb4fvte4pocml3biagbkbpm